Nature's Sunshine Products Earnings Call Transcripts
Fiscal Year 2026
-
The company outlined a strategy to double sales to $1 billion by expanding geographically, accelerating digital and retail channels, and pursuing disciplined M&A. Product innovation focuses on gut health, women's health, and skincare, with a new brand campaign launching soon.
-
Q2 net sales reached a record $117 million, up 2% year-over-year, with strong digital and regional growth, though China sales declined 20%. Gross margin hit 73.7%, and 2026 guidance was lowered due to FX and China. Strategic investments and leadership changes support long-term growth.
-
Q1 2026 delivered 9% sales and 33% EBITDA growth, led by digital expansion and strong regional performance. Guidance for 2026 is reaffirmed, with investments in technology and product innovation expected to drive sustainable growth.
Fiscal Year 2025
-
Record 2025 sales and EBITDA growth were driven by digital expansion, new customer acquisition, and strong consultant partnerships. 2026 guidance calls for 4–7% sales growth and continued investment in digital and innovation, with a long-term goal to double sales to $1 billion.
-
Record Q3 sales and profitability driven by digital and international growth, with raised 2025 guidance for both revenue and EBITDA. Strong balance sheet, robust cash flow, and new CEO position the company for continued expansion despite macro headwinds.
-
Q2 saw 4% revenue growth and 8% higher Adjusted EBITDA, led by strong digital and international performance. Full-year guidance was raised, with North America expected to drive growth and APAC moderating due to tough comps. Share repurchases and new product launches support long-term momentum.
-
Q1 2025 saw revenue and adjusted EBITDA beat expectations, driven by double-digit growth in Asia-Pacific and Europe, and strong digital sales. Guidance for 2025 remains conservative due to macro and tariff risks, but the company is well-positioned with a strong balance sheet and increased share repurchase authorization.
Fiscal Year 2024
-
Q4 revenue hit a record $118M, up 10% year-over-year, with Asia-Pacific and Europe driving growth. 2025 guidance is cautious due to macro and tariff risks, with net sales expected between $445M–$470M and adjusted EBITDA of $38M–$44M.
-
The company leverages a fully integrated, quality-focused model and omnichannel strategy to target premium health-conscious consumers globally. Digital initiatives, innovative products, and disciplined capital allocation drive growth, with a goal to significantly improve EBITDA margins over the next 3–5 years.
-
Q3 2024 saw 4% sales growth (local currency), led by APAC and digital gains, despite China weakness and margin pressure from inflation and FX. Full-year guidance was raised, with cost savings and digital investments supporting future growth.
-
A vertically integrated health and wellness company is leveraging digital, field, and brand strategies to drive growth, with strong financials, a premium product focus, and ongoing investments in digital and supply chain. Recent growth is led by digital channels and new product launches.
-
Q2 2024 net sales fell 3% in local currency, impacted by macroeconomic headwinds and a digital platform transition. Guidance for full-year sales and EBITDA was lowered, but digital and European segments are expected to drive growth in the second half.
-
A fully integrated herbal supplement leader with a global omni-channel strategy, strong digital growth, and premium product differentiation. Financial performance is robust, with expanding margins, ongoing share buybacks, and a focus on innovation and automation.